JP2024538128A5 - - Google Patents

Info

Publication number
JP2024538128A5
JP2024538128A5 JP2024522501A JP2024522501A JP2024538128A5 JP 2024538128 A5 JP2024538128 A5 JP 2024538128A5 JP 2024522501 A JP2024522501 A JP 2024522501A JP 2024522501 A JP2024522501 A JP 2024522501A JP 2024538128 A5 JP2024538128 A5 JP 2024538128A5
Authority
JP
Japan
Prior art keywords
alkyl
heteroalkyl
cancer
optionally substituted
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024522501A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024538128A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/046761 external-priority patent/WO2023064586A1/en
Publication of JP2024538128A publication Critical patent/JP2024538128A/ja
Publication of JP2024538128A5 publication Critical patent/JP2024538128A5/ja
Pending legal-status Critical Current

Links

JP2024522501A 2021-10-15 2022-10-14 Ehmt1及びehmt2の新規調節因子及びその治療用途 Pending JP2024538128A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163256057P 2021-10-15 2021-10-15
US63/256,057 2021-10-15
US202263390438P 2022-07-19 2022-07-19
US63/390,438 2022-07-19
PCT/US2022/046761 WO2023064586A1 (en) 2021-10-15 2022-10-14 Novel modulators of ehmt1 and ehmt2 and therapeutic use thereof

Publications (2)

Publication Number Publication Date
JP2024538128A JP2024538128A (ja) 2024-10-18
JP2024538128A5 true JP2024538128A5 (cg-RX-API-DMAC10.html) 2025-10-21

Family

ID=84357982

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024522501A Pending JP2024538128A (ja) 2021-10-15 2022-10-14 Ehmt1及びehmt2の新規調節因子及びその治療用途

Country Status (9)

Country Link
US (1) US20240368139A1 (cg-RX-API-DMAC10.html)
EP (1) EP4416143A1 (cg-RX-API-DMAC10.html)
JP (1) JP2024538128A (cg-RX-API-DMAC10.html)
KR (1) KR20240148310A (cg-RX-API-DMAC10.html)
AU (1) AU2022366869A1 (cg-RX-API-DMAC10.html)
CA (1) CA3234693A1 (cg-RX-API-DMAC10.html)
IL (1) IL311999A (cg-RX-API-DMAC10.html)
MX (1) MX2024004416A (cg-RX-API-DMAC10.html)
WO (1) WO2023064586A1 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116602242B (zh) * 2023-05-08 2024-01-23 中国水产科学研究院珠江水产研究所 一种提高反季鱼苗成活率的方法
WO2025155882A1 (en) * 2024-01-19 2025-07-24 Icahn School Of Medicine At Mount Sinai G9a/glp degradation / disruption compounds and methods of use

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3270960A (en) 1964-09-11 1966-09-06 Sperry Rand Corp Fluid sensor
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
IL307931A (en) * 2016-04-15 2023-12-01 Epizyme Inc Amine-substituted aryl or heteroaryl compounds as ehmt1 and ehmt2 inhibitors
MA47233A (fr) * 2016-12-19 2019-10-23 Epizyme Inc Composés hétérocycliques substitués par une amine utilisés comme inhibiteurs de l'ehmt2 et leurs méthodes d'utilisation
AU2018243749A1 (en) * 2017-03-31 2019-11-21 Epizyme, Inc. Methods of using EHMT2 inhibitors
WO2018195450A1 (en) * 2017-04-21 2018-10-25 Epizyme, Inc. Combination therapies with ehmt2 inhibitors
AU2018353150B2 (en) * 2017-10-18 2024-06-06 Epizyme, Inc. Methods of using EHMT2 inhibitors in treating or preventing blood disorders
US20210213014A1 (en) * 2017-10-18 2021-07-15 Epizyme, Inc. Methods of using ehmt2 inhibitors in immunotherapies

Similar Documents

Publication Publication Date Title
RU2013128448A (ru) Производные триазола в качестве ингибиторов сигнального пути wnt
JP2025160318A5 (cg-RX-API-DMAC10.html)
JP2020503363A5 (cg-RX-API-DMAC10.html)
HRP20160625T1 (hr) Novi inhibitori stat3 signalnog puta i inhibitori matičnih stanica raka
CN111247152B (zh) 作为激酶抑制剂的环状亚氨基嘧啶衍生物
TW202014186A (zh) 作為核轉運調節劑之化合物及其用途
RU2013156361A (ru) Новые соединения
JP2020527173A5 (cg-RX-API-DMAC10.html)
RU2018102365A (ru) Новые гидроксисложноэфирные производные, способ их получения и фармацевтические композиции, содержащие их
JP2018532737A5 (cg-RX-API-DMAC10.html)
RU2016102036A (ru) Производное хинолина
IL274504B1 (en) 2ACSS inhibitors and methods of their use
JP2023533203A5 (cg-RX-API-DMAC10.html)
JP2014513704A5 (cg-RX-API-DMAC10.html)
JP2018511628A5 (cg-RX-API-DMAC10.html)
RU2016130986A (ru) Ингибитор киназы и его применение
JP2007511504A5 (cg-RX-API-DMAC10.html)
AU2017335242A1 (en) Pyridine compound
JP2021514395A5 (cg-RX-API-DMAC10.html)
JP2020063289A5 (cg-RX-API-DMAC10.html)
CN107548391A (zh) 嘧啶或吡啶类化合物、其制备方法和医药用途
CA2991360A1 (en) 2-aryl- and 2-arylalkyl-benzimidazoles as midh1 inhibitors
JP2015504075A5 (cg-RX-API-DMAC10.html)
JP2023534528A5 (cg-RX-API-DMAC10.html)
JP2023531970A5 (cg-RX-API-DMAC10.html)